細胞免疫療法市場－全球產業規模、佔有率、趨勢、機會、預測：按療法類型、適應症、最終用途、地區和競爭格局分類，2021-2031年

全球細胞免疫療法市場預計將從 2025 年的 76.1 億美元成長到 2031 年的 135.1 億美元，複合年成長率為 10.04%。

這種特殊治療方法利用患者自身的免疫系統來識別和清除癌細胞，通常包括收集免疫細胞（例如T細胞）來攻擊特定的腫瘤抗原，對其進行基因改造，然後再重新輸注。癌症發生率的上升和監管核准的快速進展推動了市場擴張。這有效地將這些治療方法從實驗研究階段推進了標準臨床實踐階段。為了支持這一經濟勢頭，再生醫學聯盟報告稱，2024年細胞和基因治療領域的投資將成長30%，這表明這些創新開發平臺獲得了強力的資金支持。

儘管自體療法呈現強勁的成長趨勢，但由於其複雜的生產流程和高成本，市場仍面臨許多障礙。維持個人化的「靜脈到靜脈」供應鏈在物流方面的複雜性造成了嚴重的規模化問題，進而推高了治療成本。高昂的價格可能會限制患者獲得這些救命療法的機會，並阻礙細胞免疫療法在全球醫療保健領域的進一步普及和應用。

市場促進因素

全球癌症和自體免疫疾病發生率的不斷上升是細胞免疫療法市場成長的核心驅動力。由於傳統標準療法往往無法有效治療難治性惡性腫瘤，因此對能夠提供持續生物治療方法的免疫調節解決方案（例如CAR-T療法）的需求日益成長。這一成長勢頭源於癌症患者數量的不斷增加，從而迫切需要快速引入標靶細胞療法。根據美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告，預計僅在美國就將新增超過2,041,900例癌症病例。如此快速成長的患者群體迫使生物製藥公司專注於開發可擴展的治療方法，以滿足血液腫瘤和固態腫瘤領域尚未滿足的重大醫療需求。

同時，CAR-T 和基因編輯技術的快速發展正在改變商業格局，推動這些治療方法從研發階段走向盈利的主流治療方法。基因工程技術的日益精進和生產製造流程的日益穩定，正在簡化監管流程，加速產品上市和收入成長。產業領軍企業的強勁業績證明了這些創新技術的經濟可行性。例如，吉利德科學公司在 2025 年 2 月發布的 2024 年第四季及全年財報中揭露，其細胞治療產品的銷售額達到 20 億美元，較去年同期成長 6%。這項商業性進展得益於有利的法規結構。正如監管事務專業人員協會 (RAPS) 在 2025 年 1 月指出的那樣，美國食品藥物管理局 (FDA)生技藥品評估與研究中心 (CBER) 在 2024 年核准了10 項新的生技藥品核准申請，這表明 FDA 致力於加快新型生物療法的普及。

市場挑戰

自體療法所需的複雜生產基礎設施是限制全球細胞免疫療法市場進一步成長的主要障礙。這些治療方法需要針對特定患者建立「靜脈到靜脈」的供應鏈，這需要勞動密集的加工和嚴格的品管措施，因此無法享受傳統的規模經濟效益。這種物流柔軟性的不足導致銷貨成本高昂，最終形成高價市場，對許多醫療保險計劃造成沉重負擔。因此，高成本限制了保險報銷，減少了能夠接受這些治療的患者人數，並有效地限制了新參與企業的潛在市場規模。

此外，這些生產瓶頸導致市場高度集中，而非像商業性成功所需的那樣呈現廣泛分佈的市場格局。由於無法有效擴大生產規模，該行業被迫依賴數量有限的資產，阻礙了行業穩健成長所需的多元化發展。再生醫學聯盟預測，到2025年，該領域約75%的全球銷售額將來自不到10種市售產品。這種銷售的高度集中凸顯了規模化挑戰如何直接阻礙更廣泛的市場發展成為大規模生產的治療環境。

市場趨勢

將人工智慧 (AI) 應用於細胞療法藥物研發，正從根本上改變研發流程，它能夠最佳化細胞構建體的選擇，並更精準地預測治療效果。研發人員正擴大利用機器學習演算法處理大量生物資料集，從而在實驗室實驗之前快速設計出脫靶效應最小的合成受體。電腦科學的這項進步顯著縮短了研發週期。正如國際管理髮展研究院 (IMD) 於 2025 年 11 月發布的《2025 年未來準備指標》報告所述，採用人工智慧驅動的工作流程可以將識別臨床前候選藥物所需的時間縮短高達 40%。透過最大限度地減少試驗次數，這些技術降低了早期研發成本，並提高了臨床成功的機率。

同時，異體「即用型」細胞療法正成為一種明顯的發展趨勢，旨在克服第一代自體療法所面臨的物流限制。透過建立利用健康捐贈者細胞或誘導性多功能幹細胞的標準化主細胞庫，製造商可以預先生產治療劑量，從而確保即時供應並實現真正的商業性化規模生產。這項轉變正獲得監管機構的大力支持。例如，Reprocell 於 2025 年 9 月發表的報導《FDA 幹細胞核准和臨床試驗 2023-2025》重點介紹了 Fate Therapeutics 公司用於治療全身性紅斑性狼瘡的即用型 iPS 細胞衍生 CAR-T 療法於 2025 年 4 月獲得 FDA 的 RMAT 資格認定。隨著這些平台的成熟，它們有望透過消除目前阻礙市場擴張的複雜供應鏈，擴大治療的可及性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞免疫療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 治療方法（CAR T 細胞療法、樹突細胞療法、NK 細胞療法、TIL 療法等）
  • 適應症（B細胞惡性腫瘤、攝護腺癌、肝癌、腎細胞癌等）
  • 依最終用途（醫院、癌症研究所、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞免疫療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細胞免疫療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細胞免疫療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細胞免疫療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲細胞免疫療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球細胞免疫療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bristol-Myers Squibb Company
• Novartis AG
• Gilead Sciences Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• GlaxoSmithKline plc
• AstraZeneca Plc
• Pfizer Inc.
• Johnson & Johnson
• Celyad

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cellular Immunotherapy Market is projected to expand from USD 7.61 Billion in 2025 to USD 13.51 Billion by 2031, reflecting a compound annual growth rate of 10.04%. This specialized therapeutic modality leverages the patient's own immune system to identify and eradicate cancer cells, typically involving the extraction, genetic modification, and reinfusion of immune cells like T-cells to attack specific tumor antigens. Market expansion is propelled by the increasing incidence of oncological diseases and the rapid pace of regulatory endorsements, which have effectively shifted these therapies from experimental research into standard clinical practice. Highlighting this financial momentum, the Alliance for Regenerative Medicine reported a 30 percent increase in investment within the cell and gene therapy sector in 2024, signaling strong capital support for these innovative development pipelines.

Despite this positive growth trend, the market encounters substantial obstacles stemming from the intricate and expensive manufacturing protocols necessary for autologous therapies. The logistical complexity of sustaining a personalized, vein-to-vein supply chain introduces significant scalability issues and results in elevated treatment costs. These high price points pose a risk of restricting patient access to these life-saving interventions, potentially hindering the broader expansion and adoption of cellular immunotherapies within the global healthcare landscape.

Market Driver

The rising global prevalence of cancer and autoimmune disorders acts as the central engine for the growth of the cellular immunotherapy market. With traditional treatment standards frequently resulting in inadequate outcomes for refractory malignancies, there is an intensified demand for immune-modulating solutions, such as CAR-T therapy, to provide durable biological remedies. This momentum is rooted in the increasing demographic weight of oncological conditions, necessitating the swift implementation of targeted cellular treatments. According to the American Cancer Society's "Cancer Facts & Figures 2025" report released in January 2025, over 2,041,900 new cancer diagnoses were projected for the United States alone. This burgeoning patient base compels biopharmaceutical developers to focus on creating scalable therapies that can address severe unmet medical needs across both hematological and solid tumor categories.

Concurrently, rapid technological progress in CAR-T and gene editing is reshaping the commercial environment, facilitating the evolution of these therapies from research pipelines into profitable, mainstream offerings. Refinements in genetic engineering and manufacturing consistency have smoothed the regulatory pathway, encouraging market adoption and revenue expansion. The financial viability of these innovations is demonstrated by the strong performance of key industry leaders; for instance, Gilead Sciences reported in their February 2025 "Fourth Quarter and Full Year 2024 Financial Results" that Cell Therapy product sales rose by 6 percent year-over-year to reach USD 2.0 billion. This commercial advancement is bolstered by a supportive regulatory framework, as highlighted by the Regulatory Affairs Professionals Society in January 2025, noting that the FDA's Center for Biologics Evaluation and Research approved 10 new biological license applications in 2024, demonstrating a dedicated effort to expedite access to novel biological therapies.

Market Challenge

The intricate manufacturing infrastructure required for autologous therapies represents a primary barrier limiting the broader growth of the Global Cellular Immunotherapy Market. Since these treatments necessitate a personalized, vein-to-vein supply chain, they require labor-intensive processing and stringent quality control measures that preclude traditional economies of scale. This logistical inflexibility leads to high costs of goods sold, resulting in elevated market prices that are difficult for many healthcare systems to support. As a result, these high costs restrict reimbursement coverage and reduce the number of patients who can afford these interventions, effectively placing a cap on the potential market volume for new industry entrants.

Furthermore, these manufacturing bottlenecks have created a market landscape where commercial success is highly concentrated rather than widely distributed. The inability to achieve efficient production scalability compels the industry to depend on a limited number of assets, which inhibits the diversification required for robust sector growth. According to the Alliance for Regenerative Medicine in 2025, approximately 75 percent of the global revenue in this field is derived from fewer than ten commercialized products. This significant revenue concentration highlights how scalability challenges directly prevent the broader market from evolving into a high-volume therapeutic landscape.

Market Trends

The integration of artificial intelligence into cell therapy discovery is fundamentally transforming research and development by optimizing the selection of cellular constructs and predicting therapeutic efficacy with greater accuracy. Developers are increasingly utilizing machine learning algorithms to process extensive biological datasets, enabling the rapid design of synthetic receptors that minimize off-target effects prior to wet-lab experimentation. This computational evolution is drastically shortening development schedules; as noted by the International Institute for Management Development in their "Future Readiness Indicator 2025" report from November 2025, incorporating AI-driven workflows can reduce the time needed to identify preclinical candidates by as much as 40 percent. By minimizing trial-and-error iterations, these technologies lower early-stage expenditures and improve the likelihood of clinical success.

Simultaneously, there is a distinct trend toward allogeneic "off-the-shelf" cell therapies designed to overcome the logistical constraints associated with first-generation autologous treatments. By leveraging healthy donor cells or induced pluripotent stem cells to establish standardized master cell banks, manufacturers can produce therapeutic doses in advance, ensuring immediate availability and facilitating true commercial scalability. This shift is gathering significant regulatory support; for example, Reprocell's September 2025 article, "Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025," highlights that Fate Therapeutics' off-the-shelf iPSC-derived CAR-T therapy for systemic lupus erythematosus received FDA RMAT designation in April 2025. As these platforms mature, they hold the promise of democratizing access by dismantling the complicated supply chains that currently hinder market expansion.

Key Market Players

• Bristol-Myers Squibb Company
• Novartis AG
• Gilead Sciences Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• GlaxoSmithKline plc
• AstraZeneca Plc
• Pfizer Inc.
• Johnson & Johnson
• Celyad

Report Scope

In this report, the Global Cellular Immunotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cellular Immunotherapy Market, By Therapy Type

• CAR T Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy
• TIL Therapy
• Others

Cellular Immunotherapy Market, By Indication

• B-cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

Cellular Immunotherapy Market, By End-Use

• Hospitals
• Cancer Institutes
• Others

Cellular Immunotherapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cellular Immunotherapy Market.

Available Customizations:

Global Cellular Immunotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cellular Immunotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others)
  • 5.2.2. By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others)
  • 5.2.3. By End-Use (Hospitals, Cancer Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cellular Immunotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Indication
  • 6.2.3. By End-Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cellular Immunotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Canada Cellular Immunotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Mexico Cellular Immunotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End-Use

7. Europe Cellular Immunotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Indication
  • 7.2.3. By End-Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cellular Immunotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End-Use
  • 7.3.2. France Cellular Immunotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom Cellular Immunotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy Cellular Immunotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain Cellular Immunotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End-Use

8. Asia Pacific Cellular Immunotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Indication
  • 8.2.3. By End-Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cellular Immunotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India Cellular Immunotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End-Use
  • 8.3.3. Japan Cellular Immunotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End-Use
  • 8.3.4. South Korea Cellular Immunotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia Cellular Immunotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End-Use

9. Middle East & Africa Cellular Immunotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Indication
  • 9.2.3. By End-Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cellular Immunotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End-Use
  • 9.3.2. UAE Cellular Immunotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End-Use
  • 9.3.3. South Africa Cellular Immunotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End-Use

10. South America Cellular Immunotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Indication
  • 10.2.3. By End-Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cellular Immunotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Colombia Cellular Immunotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End-Use
  • 10.3.3. Argentina Cellular Immunotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cellular Immunotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Gilead Sciences Inc.
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Merck KGaA
• 15.6. GlaxoSmithKline plc
• 15.7. AstraZeneca Plc
• 15.8. Pfizer Inc.
• 15.9. Johnson & Johnson
• 15.10. Celyad

16. Strategic Recommendations

17. About Us & Disclaimer